Adaptive Biotechnologies Corp
(STU:1HM)
€
5.052
0.316 (6.67%)
Market Cap: 756.77 Mil
Enterprise Value: 574.96 Mil
PE Ratio: 0
PB Ratio: 3.21
GF Score: 78/100 Adaptive Biotechnologies Corp at Cowen Health Care Conference (Virtual) Transcript
Mar 09, 2022 / 02:50PM GMT
Release Date Price:
€11
(+6.80%)
Daniel Gregory Brennan
Cowen and Company, LLC, Research Division - Research Analyst
Good morning. Welcome to Day 3 of the Cowen Healthcare Conference. I'm Dan Brennan, one of the tools and diagnostics analyst here. Really pleased to be joined with me on the virtual stage here, Chad Robins, Co-Founder, CEO, Chairman of Adaptive Bio. I have known Chad for a while. So first off, just, Chad, welcome and thanks for being here.
Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman
Hey Dan, thanks for having me. It's great to be back at Cowen.
Questions & Answers
Daniel Gregory Brennan
Cowen and Company, LLC, Research Division - Research Analyst
Awesome. So I'd like to kick it off just with the news out today a couple of announcements. So first, Tycho Peterson, the new CFO. Secondly, you announced the reorientation of the business under MRD and immune medicine, which have been discussed and then also a workforce reduction. So first, on Tycho, that's awesome. He's going to be
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot